Madrigal Appoints Johnson & Johnson R&D Chief John Reed to Board

Management
โดย GlobeNewswire·US·Read original
Summary · why it matters

Madrigal Pharmaceuticals has appointed John C. Reed, M.D., Ph.D., to its board of directors. Dr. Reed is Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson and a member of its Executive Committee. Madrigal’s Chairman Julian Baker and CEO Bill Sibold highlighted his track record in advancing innovative medicines and his strategic leadership, which they expect will support the company’s growth and its MASH pipeline, including the launched therapy Rezdiffra.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 2 stocks
© 2026 MarketDXNews